Search results for "Biologic marker"

showing 4 items of 4 documents

Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.

2002

PURPOSE: To study safety, feasibility, and biologic activity of adenovirus-mediated p53 gene transfer in patients with bladder cancer. PATIENTS AND METHODS: Twelve patients with histologically confirmed bladder cancer scheduled for cystectomy were treated on day 1 with a single intratumoral injection of SCH 58500 (rAd/p53) at cystoscopy at one dose level (7.5 × 1011 particles) or a single intravesical instillation of SCH 58500 with a transduction-enhancing agent (Big CHAP) at three dose levels (7.5 × 1011 to 7.5 × 1013 particles). Cystectomies were performed in 11 patients on day 3, and transgene expression, vector distribution, and biologic markers of transgene activity were assessed by m…

AdultCancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentGenetic enhancementGenetic VectorsUrologyCystectomyAdenoviridaeCystectomymedicineHumansNeoplasm InvasivenessAgedDNA PrimersBiologic markerAged 80 and overUrinary bladderBladder cancermedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryReverse Transcriptase Polymerase Chain ReactionGenetic transferGene Transfer TechniquesCystoscopyGenetic TherapyMiddle Agedmedicine.diseaseGenes p53medicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsImmunohistochemistrybusinessJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life

2020

Background: Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We evaluated MEP efficacy on lung function, symptoms, asthma exacerbations, biologic markers, steroid dependence and controller treatment level in real-life. Methods: We retrospectively analyzed 134 severe asthmatics (61 males; mean age 58.3 ± 11; mean FEV1%:72 ± 21), treated with MEP for at least 6 months (mean duration:10.9 ± 3.7 months). Results: FEV1% improved significantly after MEP. Mean FEF25-75 also increased from 37.4 ± 25.4% to 47.2 ± 27.2% (p < 0.0001). Mean baseline blood eosinophil level was 712 ± 731/μ…

MaleOmalizumabFEF(25-75)step-down0302 clinical medicineMaintenance therapyAdrenal Cortex HormonesSettore MED/10Pharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicinesmall airwaysAsthma exacerbationsmepolizumabMiddle AgedAnesthesiaFEF25-75CorticosteroidDrug Therapy CombinationFemalemedicine.drugPulmonary and Respiratory Medicinesevere asthmamedicine.drug_classMepolizumab Severe asthma Real-life Small airways FEF25-75 Oral corticosteroids Step-down EffectiveneseffectivenessSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroidsAntibodies Monoclonal HumanizedNO03 medical and health sciencesEffectiveness FEF 25-75 Mepolizumab Oral corticosteroids Real-life Severe asthma Small airways Step-downmedicineHumansIn real lifeFEFreal-lifeAgedRetrospective StudiesBiologic markerbusiness.industryEffectivenesBiochemistry (medical)Effectiveness; FEF; 25-75; Mepolizumab; Oral corticosteroids; Real-life; Severe asthma; Small airways; Step-downAirway obstructionmedicine.diseaseAsthmaBlood Cell Countrespiratory tract diseasesAirway ObstructionEosinophils030228 respiratory systemeffectiveness; FEF(25-75); mepolizumab; oral corticosteroids; real-life; severe asthma; small airways; step-down25-75businessMepolizumab
researchProduct

Biological aggressiveness evaluation in prostate carcinomas: immunohistochemical analysis of PCNA and p53 in a series of Gleason 6 (3+3) adenocarcino…

2003

We selected 63 prostate tumors with Gleason's grade 6 (3+3), commonly showing both tubular and cribrous patterns. We compared in both patterns the expression of two of the most used biologic markers: PCNA and p53, with the aim to verify the validity of the Gleason's grading system to compare the morphologic grade with biologic aggressiveness and prognostic value. We did not find any statistical difference in the protein immunopositivity, indicating that both patterns could have identical biologic behaviour; then we confirmed the validity of Gleason's system for considering both tubular and cribrous patterns as an intermediate grade of tumoral differentiation. Moreover, we found a linear rel…

MalePathologymedicine.medical_specialtyHistologyProliferative indexBiophysicsStatistical differenceSettore MED/08 - Anatomia PatologicaAdenocarcinomaBiologyP53 MutationProstateProliferative index; Prostate cancerogenesis; Tumoral differentiation; Tumoral prognosis; Cell Biology; Anatomy; Animal Science and Zoology; Developmental BiologyProliferating Cell Nuclear AntigenBiomarkers TumormedicineHumansProstate tumorsIntermediate Gradelcsh:QH301-705.5Tumoral differentiationBiologic markerProstatic NeoplasmsCell BiologyImmunohistochemistryProliferating cell nuclear antigenmedicine.anatomical_structurelcsh:Biology (General)Prostate cancerogenesibiology.proteinImmunohistochemistryTumoral prognosiAnimal Science and ZoologyAnatomyTumor Suppressor Protein p53Developmental BiologyEuropean Journal of Histochemistry
researchProduct

Sentinel node biopsy for malignant melanoma: a staging procedure only?

2010

Sentinel node biopsy (SNB) is an established staging tool for malignant melanoma. It allows identification of patients with metastatic disease at a very early stage and to collect accurate and complete prognostic information for these patients. Having noted that in a relevant percentage of patients the sentinel node is the only site of metastases, some authors have postulated a therapeutic role for SNB. In this paper, the possibility of a therapeutic role of SNB is evaluated. Relevant literature on the topic has been analyzed. Several findings suggest that not all patients with a positive SNB have further lymph node involvement. The prognostic indicators currently available do not significa…

OncologyBiologic markermedicine.medical_specialtymedicine.diagnostic_testbusiness.industryMelanomaSettore MED/19 - Chirurgia PlasticaDiseaseSentinel nodemedicine.diseasemedicine.anatomical_structureSentinel lymph node biopsy melanoma . Melanoma lymph node metastases . Melanoma prognosis . Prognostic false positivity . Melanoma lymphadenectomyInternal medicineStaging procedureBiopsymedicineSurgeryStage (cooking)businessLymph nodeEuropean Journal of Plastic Surgery
researchProduct